24 February 2018 in In Vivo

Species: mouse and rat.
Follow-up period: typically 2-6 weeks
Route of compound administration: topical, intravitreal, subretinal, systemic
• In vivo imaging (fundoscopy, optical coherence tomography (OCT))
• In vivo functional assessment: a) electroretinography (ERG), b) visual evoked potential measurements (VEP)
• Morphological assessment (histology, IHC, EM, stereology)
• Molecular biology (ELISA, Western blotting, qPCR)

Our key references:
Kaja S, Naumchuk Y, Grillo SL, Borden PK, Koulen P. Differential up-regulation of Vesl-1/Homer 1 protein isoforms associated with decline in visual performance in a preclinical glaucoma model. Vision Res. 2014 Jan;94:16-23.

Kalesnykas G, Oglesby EN, Zack DJ, Cone FE, Steinhart MR, Tian J, Pease ME, Quigley HA. Retinal ganglion cell morphology after optic nerve crush and experimental glaucoma. Invest Ophthalmol Vis Sci. 2012 Jun 22;53(7):3847-57.

Niittykoski M, Kalesnykas G, Larsson KP, Kaarniranta K, Akerman KE, Uusitalo H. Altered calcium signaling in an experimental model of glaucoma. Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6387-93.

For more information contact us directly.